Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

Sangamo Therapeutics (SGMO) Accumulated Depreciation & Amortization (2016 - 2025)

Sangamo Therapeutics has reported Accumulated Depreciation & Amortization over the past 15 years, most recently at $4.0 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization fell 21.68% year-over-year to $4.0 million; the TTM value through Dec 2025 reached $4.0 million, down 21.68%, while the annual FY2025 figure was $4.0 million, 21.68% down from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $4.0 million at Sangamo Therapeutics, down from $5.1 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $15.1 million in Q4 2023 and troughed at $4.0 million in Q4 2025.
  • A 5-year average of $9.1 million and a median of $9.4 million in 2021 define the central range for Accumulated Depreciation & Amortization.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: surged 64.91% in 2021 and later crashed 66.1% in 2024.
  • Year by year, Accumulated Depreciation & Amortization stood at $9.4 million in 2021, then increased by 28.81% to $12.1 million in 2022, then grew by 24.42% to $15.1 million in 2023, then crashed by 66.1% to $5.1 million in 2024, then fell by 21.68% to $4.0 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for SGMO at $4.0 million in Q4 2025, $5.1 million in Q4 2024, and $15.1 million in Q4 2023.